pharmaceutical-investing Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo Phase 1 Combination Trial
Ziopharm Oncology Responds to Recent Stock Decline and Clarifies Exclusivity Rights for Clinical Assets
Kobo Resources Extends Gold Mineralisation at Depth and Further Defines the Contact Zone Fault Target
